Ignite Creation Date:
2025-12-24 @ 7:49 PM
Ignite Modification Date:
2026-04-12 @ 3:47 AM
Study NCT ID:
NCT06854003
Status:
RECRUITING
Last Update Posted:
2025-10-29
First Post:
2025-02-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Sponsor:
Christine Ryan
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
24-654
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |